Rat's Rant: What's hot, what's not and ... more biotech winners
Finfeed
Archived
Oct 03, 2019
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.